CA2390789A1 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
CA2390789A1
CA2390789A1 CA002390789A CA2390789A CA2390789A1 CA 2390789 A1 CA2390789 A1 CA 2390789A1 CA 002390789 A CA002390789 A CA 002390789A CA 2390789 A CA2390789 A CA 2390789A CA 2390789 A1 CA2390789 A1 CA 2390789A1
Authority
CA
Canada
Prior art keywords
ethyl
propoxy
fluorophenyl
hydroxyphenoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390789A
Other languages
English (en)
French (fr)
Inventor
Beverly Ann Teicher
Douglas Wade Beight
Edward C. R. Smith
William Thomas Mcmillen
Jerome Herbert Fleisch
Jason Scott Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2390789A1 publication Critical patent/CA2390789A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002390789A 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer Abandoned CA2390789A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16471399P 1999-11-11 1999-11-11
US60/164,713 1999-11-11
PCT/US2000/030944 WO2001034135A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2390789A1 true CA2390789A1 (en) 2001-05-17

Family

ID=22595757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390789A Abandoned CA2390789A1 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (5)

Country Link
EP (1) EP1231939A2 (ja)
JP (1) JP2003513914A (ja)
AU (1) AU2041801A (ja)
CA (1) CA2390789A1 (ja)
WO (1) WO2001034135A2 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
WO2001085166A1 (en) * 2000-05-09 2001-11-15 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
EP1311262A4 (en) 2000-07-28 2005-06-01 Cancer Rec Tech Ltd COMBINED TREATMENT AGAINST CANCER
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP2080751A4 (en) 2006-10-12 2011-06-22 Inst Med Molecular Design Inc CARBOXYLIC ACID DERIVATIVE
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
BR112014016450A2 (pt) 2012-01-10 2019-09-24 Lilly Co Eli composto antagonista de leucotrieno b4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES537162A0 (es) * 1983-10-31 1985-12-01 Merck Frosst Canada Inc Una composicion farmaceutica
US4704400A (en) * 1986-06-24 1987-11-03 Merck & Co., Inc. Medicarpin derivatives and analogs
ES2062943B1 (es) * 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
EP1231939A2 (en) 2002-08-21
AU2041801A (en) 2001-06-06
WO2001034135A2 (en) 2001-05-17
JP2003513914A (ja) 2003-04-15
WO2001034135A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU778829B2 (en) Oncolytic combinations for the treatment of cancer
JP6364028B2 (ja) 選択的エストロゲン受容体ディグレーダーとしてのベンゾチオフェン誘導体およびその組成物
RU2529868C2 (ru) Производное индолизина и его применение в медицинских целях
ES2397664T3 (es) Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
ES2547153T3 (es) Derivados de 8-alcoxi-aminotetralina sustituidos y su uso
TWI331034B (en) Inhibitors of cyclin-dependent kinases and their use
JP2003531194A (ja) プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物
TW446704B (en) Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia
CA2390789A1 (en) Oncolytic combinations for the treatment of cancer
TW200418801A (en) Isoquinolinone derivatives and their use as therapeutic agents
JP2003509419A (ja) カルボン酸類およびアシルスルホンアミド類、そのような化合物を含む組成物、ならびに治療方法
WO2005079803A1 (en) Compounds for treatment of cardiovascular diseases
WO2001034198A2 (en) Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) Oncolytic combinations for the treatment of cancer
JP6223336B2 (ja) 新規なエストロゲン受容体リガンド
ES2207108T3 (es) Derivados de acido aril carboxilico y tetrazol con un grupo de carbamoiloxi.
US20060160773A1 (en) Combretastatin derivatives with cytotoxic action
WO2019031470A1 (ja) 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
US9079876B2 (en) Imidazole derivatives and preparation method and use thereof
KR101360579B1 (ko) 신규 페닐초산 유도체
Ma et al. New β-carboline derivatives containing imidazolium as potential VEGFR2 inhibitors: synthesis, X-ray structure, antiproliferative evaluations, and molecular modeling
ES2843979T3 (es) Composiciones para el tratamiento de enfermedades renales y/o hepáticas
JP7345899B2 (ja) リン酸塩誘導体およびその用途
JPH02124889A (ja) イミダゾピラゾール誘導体
JP2014532644A (ja) Ｒａｒアンタゴニストとしての置換ピラゾール類似体

Legal Events

Date Code Title Description
FZDE Dead